

Financial Overview Q2 2010

| in million of Euros | DSM | | | Nutrition | | | Pharma | | | Performance Materials | | | Polymer Intermediates | | | Base Chemicals & Materials | | | Other | | |
|--------------------------------------|-------|-------|-------|-----------|-------|-------|--------|-------|-------|-----------------------|-------|-------|-----------------------|-------|-------|----------------------------|-------|-------|-------|-------|--------|
| <i>Continuing operations</i> | | | | | | | | | | | | | | | | | | | | | |
| <i>before exceptional</i> | Q2'10 | Q2'09 | Chg.% | Q2'10 | Q2'09 | Chg.% | Q2'10 | Q2'09 | Chg.% | Q2'10 | Q2'09 | Chg.% | Q2'10 | Q2'09 | Chg.% | Q2'10 | Q2'09 | Chg.% | Q2'10 | Q2'09 | Chg.% |
| Sales | 2268 | 1772 | 28% | 764 | 699 | 9% | 195 | 177 | 10% | 644 | 456 | 41% | 362 | 215 | 68% | 193 | 139 | 39% | 110 | 86 | 28% |
| Organic growth | | | 23% | | | 4% | | | 5% | | | 35% | | | 60% | | | 35% | | | |
| Volume | | | 13% | | | 6% | | | 5% | | | 27% | | | -9% | | | 27% | | | |
| Price | | | 10% | | | -2% | | | - | | | 8% | | | 69% | | | 8% | | | |
| Exchange rates | | | 5% | | | 5% | | | 5% | | | 4% | | | 8% | | | 4% | | | |
| Other | | | | | | | | | | | | 2% | | | | | | | | | |
| EBITDA | 354 | 186 | 90% | 193 | 156 | 24% | 15 | 18 | -17% | 88 | 44 | 100% | 62 | 11 | 464% | 29 | -2 | | -33 | -41 | -0.195 |
| EBITDA margin (%) | 15.6% | 10.5% | | 25.3% | 22.3% | | 7.7% | 10.2% | | 13.7% | 9.6% | | 17.1% | 5.1% | | 15.0% | -1.4% | | | | |
| DA | 108 | 101 | | 35 | 32 | | 15 | 15 | | 30 | 27 | | 8 | 7 | | 7 | 8 | | | | |
| EBIT | 246 | 85 | 189% | 158 | 124 | 27% | 0 | 3 | -100% | 58 | 17 | 241% | 54 | 4 | 1250% | 22 | -10 | | -46 | -53 | -13% |
| EBIT margin (%) | 10.8% | 4.8% | | 20.7% | 17.7% | | 0.0% | 1.7% | | 9.0% | 3.7% | | 14.9% | 1.9% | | 11.4% | -7% | | | | |
| EPS | 0.94 | 0.22 | | | | | | | | | | | | | | | | | | | |
| <i>Total DSM before exceptionals</i> | | | | | | | | | | | | | | | | | | | | | |
| EBIT | 252 | 79 | 219% | | | | | | | | | | | | | | | | | | |
| Net Profit | 158 | 30 | 427% | | | | | | | | | | | | | | | | | | |
| <i>Total DSM incl exceptionals</i> | | | | | | | | | | | | | | | | | | | | | |
| Net Profit | 149 | 10 | | | | | | | | | | | | | | | | | | | |
| EPS | 0.90 | 0.05 | | | | | | | | | | | | | | | | | | | |

Disclaimer

This document is offered for your convenience and DSM has carefully checked the provided information. However, DSM makes no representations or warranties as to the completeness, timeliness or accuracy of any information contained herein. DSM assumes no liability or responsibility for any errors, omissions or possible obsolescence in the content of this document. The information offered herein does not constitute legal advice. Nothing contained in this document is, or should be relied upon as, a promise or forecast of the future. One should rely solely on its own judgment, review and business analysis in evaluating the provided information.

Unlimited. **DSM**

Financial Overview H1 2010

| in million of Euros | DSM | | | Nutrition | | | Pharma | | | Performance Materials | | | Polymer Intermediates | | | Base Chemicals & Materials | | | Other | | |
|--------------------------------------|-------|-------|-------|-----------|-------|-------|--------|-------|-------|-----------------------|-------|-------|-----------------------|-------|-------|----------------------------|-------|-------|-------|-------|-------|
| <i>Continuing operations</i> | | | | | | | | | | | | | | | | | | | | | |
| <i>before exceptional</i> | H1'10 | H1'09 | Chg.% | H1'10 | H1'09 | Chg.% | H1'10 | H1'09 | Chg.% | H1'10 | H1'09 | Chg.% | H1'10 | H1'09 | Chg.% | H1'10 | H1'09 | Chg.% | H1'10 | H1'09 | Chg.% |
| Sales | 4331 | 3442 | 26% | 1496 | 1406 | 6% | 381 | 374 | 2% | 1201 | 851 | 41% | 676 | 354 | 91% | 364 | 261 | 40% | 213 | 196 | 9% |
| Organic growth | | | 24% | | | 5% | | | 0% | | | 38% | | | 90% | | | 38% | | | |
| Volume | | | 19% | | | 10% | | | 2% | | | 32% | | | 29% | | | 33% | | | |
| Price | | | 5% | | | -5% | | | -2% | | | 6% | | | 61% | | | 5% | | | |
| Exchange rates | | | 1% | | | 1% | | | 2% | | | 1% | | | 1% | | | 2% | | | |
| Other | | | 1% | | | | | | | | | 2% | | | | | | | | | |
| EBITDA | 655 | 325 | 102% | 364 | 330 | 10% | 30 | 43 | -30% | 163 | 50 | 226% | 113 | -11 | | 51 | -12 | | -66 | -75 | -0.12 |
| EBITDA margin (%) | 15.1% | 9.4% | | 24.3% | 23.5% | | 7.9% | 11.5% | | 13.6% | 5.9% | | 16.7% | -3.1% | | 14.0% | -4.6% | | | | |
| DA | 215 | 198 | | 68 | 65 | | 29 | 29 | | 62 | 50 | | 16 | 15 | | 13 | 15 | | | | |
| EBIT | 440 | 127 | 246% | 296 | 265 | 12% | 1 | 14 | -93% | 101 | 0 | | 97 | -26 | | 38 | -27 | | -93 | -99 | -6% |
| EBIT margin (%) | 10.2% | 3.7% | | 19.8% | 18.8% | | 0.3% | 3.7% | | 8.4% | 0.0% | | 14.3% | -7.3% | | 10.4% | -10% | | | | |
| EPS | 1.70 | 0.28 | | | | | | | | | | | | | | | | | | | |
| <i>Total DSM before exceptionals</i> | | | | | | | | | | | | | | | | | | | | | |
| EBIT | 470 | 136 | 246% | | | | | | | | | | | | | | | | | | |
| Net Profit | 302 | 55 | 449% | | | | | | | | | | | | | | | | | | |
| <i>Total DSM incl exceptionals</i> | | | | | | | | | | | | | | | | | | | | | |
| Net Profit | 279 | 23 | | | | | | | | | | | | | | | | | | | |
| EPS | 1.68 | 0.11 | | | | | | | | | | | | | | | | | | | |

Disclaimer

This document is offered for your convenience and DSM has carefully checked the provided information. However, DSM makes no representations or warranties as to the completeness, timeliness or accuracy of any information contained herein. DSM assumes no liability or responsibility for any errors, omissions or possible obsolescence in the content of this document. The information offered herein does not constitute legal advice. Nothing contained in this document is, or should be relied upon as, a promise or forecast of the future. One should rely solely on its own judgment, review and business analysis in evaluating the provided information.

Unlimited. **DSM**